Cargando…

Influence of age on the effectiveness and duration of protection of Vaxzevria and CoronaVac vaccines: A population-based study

BACKGROUND: Aging influences COVID-19 severity and response to vaccination, but previous vaccine effectiveness (VE) analyzes lack the power to evaluate its role in subgroups within the elderly age group. Here we analyzed the impact of age on viral vector and inactivated virus vaccines' effectiv...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cerqueira-Silva, Thiago, Oliveira, Vinicius de Araújo, Boaventura, Viviane S., Pescarini, Julia M., Júnior, Juracy Bertoldo, Machado, Tales Mota, Flores-Ortiz, Renzo, Penna, Gerson O., Ichihara, Maria Yury, de Barros, Jacson Venâncio, Barreto, Mauricio L., Werneck, Guilherme Loureiro, Barral-Netto, Manoel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8692070/ https://www.ncbi.nlm.nih.gov/pubmed/34957437 http://dx.doi.org/10.1016/j.lana.2021.100154

Ejemplares similares

Duration of protection of CoronaVac plus heterologous BNT162b2 booster in the Omicron period in Brazil
por: Cerqueira-Silva, Thiago, et al.
Publicado: (2022)

Vaccine effectiveness of heterologous CoronaVac plus BNT162b2 in Brazil
por: Cerqueira-Silva, Thiago, et al.
Publicado: (2022)

CoronaVac vaccine is effective in preventing symptomatic and severe COVID-19 in pregnant women in Brazil: a test-negative case-control study
por: Paixao, Enny S., et al.
Publicado: (2022)

Vaccine effectiveness of CoronaVac against COVID-19 among children in Brazil during the Omicron period
por: Florentino, Pilar T. V., et al.
Publicado: (2022)

Effectiveness of BNT162b2 booster after CoronaVac primary regimen in pregnant people during omicron period in Brazil
por: Florentino, Pilar T V, et al.
Publicado: (2022)

Effectiveness of CoronaVac, ChAdOx1 nCoV-19, BNT162b2, and Ad26.COV2.S among individuals with previous SARS-CoV-2 infection in Brazil: a test-negative, case-control study
por: Cerqueira-Silva, Thiago, et al.
Publicado: (2022)

Boosting immunity after CoronaVac
por: Sester, Martina, et al.
Publicado: (2022)

Immunogenicity of Mix-and-Match CoronaVac/BNT162b2 Regimen versus Homologous CoronaVac/CoronaVac Vaccination: A Single-Blinded, Randomized, Parallel Group Superiority Trial
por: Samoud, Samar, et al.
Publicado: (2023)

CoronaVac efficacy data from Turkey
por: McMenamin, Martina E, et al.
Publicado: (2021)

CoronaVac: more data for regulators and policy makers
por: Ramasamy, Maheshi N, et al.
Publicado: (2021)

Minimal change disease following vaccination with CoronaVac
por: Dirim, Ahmet Burak, et al.
Publicado: (2021)

Humoral Immune Response to CoronaVac in Turkish Adults
por: Cosgun, Yasemin, et al.
Publicado: (2023)

ANCA-associated vasculitis following the CoronaVac vaccination
por: Ma, Yaohui, et al.
Publicado: (2022)

Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial
por: Li, Jingxin, et al.
Publicado: (2022)

CoronaVac efficacy data from Turkey – Authors' reply
por: Tanriover, Mine Durusu, et al.
Publicado: (2021)

Leukocytoclastic vasculitis after the third dose of CoronaVac vaccination
por: Oskay, T., et al.
Publicado: (2021)

Effectiveness of CoronaVac in preventing COVID-19 in healthcare workers
por: Bayhan, Gulsum Iclal, et al.
Publicado: (2022)

Antibody dynamics post-Comirnaty and CoronaVac vaccination in Malaysia
por: Tan, Cheng Siang, et al.
Publicado: (2022)

Cutaneous reactions after CoronaVac and BioNTech vaccines
por: Öner, Ümran, et al.
Publicado: (2022)

A Randomized Clinical Trial Using CoronaVac or BNT162b2 Vaccine as a Third Dose in Adults Vaccinated with Two Doses of CoronaVac
por: Mok, Chris Ka Pun, et al.
Publicado: (2022)

Evaluation and follow-up of antibody formation after CoronaVac vaccine
por: Çalişir, Büşra, et al.
Publicado: (2022)

Phenotypic and functional changes of T cell subsets after CoronaVac vaccination
por: Phoksawat, Wisitsak, et al.
Publicado: (2022)

Anaphylaxis is rare due to CoronaVac in a population of healthcare workers
por: Öztürk, Betül Özdel, et al.
Publicado: (2022)

Effectiveness of mRNA boosters after homologous primary series with BNT162b2 or ChAdOx1 against symptomatic infection and severe COVID-19 in Brazil and Scotland: A test-negative design case–control study
por: Cerqueira-Silva, Thiago, et al.
Publicado: (2023)

Safety and immunogenicity of CoronaVac in people living with HIV: a prospective cohort study
por: Netto, Lucas C, et al.
Publicado: (2022)

Comparative Safety and Effectiveness of Heterologous CoronaVac–ChAdOx1 versus Homologous CoronaVac Vaccination in a Real-World Setting: A Retrospective Cohort Study
por: Ruenkham, Ayakarn, et al.
Publicado: (2023)

BNT162b2 or CoronaVac as the Third Dose against Omicron: Neutralizing Antibody Responses among Transplant Recipients Who Had Received Two Doses of CoronaVac
por: Erol, Çiğdem, et al.
Publicado: (2023)

Vaccine coverage and effectiveness against laboratory-confirmed symptomatic and severe Covid-19 in indigenous people in Brazil: a cohort study
por: Pescarini, Julia M., et al.
Publicado: (2023)

Reduced CoronaVac vaccine antibody response in patients with chronic kidney disease
por: Akpolat, Tekin
Publicado: (2021)

CoronaVac or BNT162b2 Vaccine as a Third Dose
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2022)

Neutralizing antibodies induced by homologous and heterologous boosters in CoronaVac vaccines in Chile
por: Acevedo, Johanna, et al.
Publicado: (2023)

Longitudinal evaluation of innate immune responses to three doses of CoronaVac vaccine
por: Cao, Cheng, et al.
Publicado: (2023)

Immunogenicity and safety of the CoronaVac vaccine in patients with cancer receiving active systemic therapy
por: Karacin, Cengiz, et al.
Publicado: (2021)

CoronaVac COVID-19 Vaccine-Induced Anaphylaxis: Clinical Characteristics and Revaccination Outcomes
por: Laisuan, Wannada, et al.
Publicado: (2021)

Effectiveness of the CoronaVac® vaccine in a region of the Colombian Amazon, was herd immunity achieved?
por: Serrano-Coll, Héctor, et al.
Publicado: (2022)

Breakthrough COVID-19 case after full-dose administration of CoronaVac vaccine
por: Ulhaq, Zulvikar Syambani, et al.
Publicado: (2021)

Heterologous booster vaccination with CoronaVac following prime vaccination with mRNA vaccine
por: Goh, Yun Shan, et al.
Publicado: (2022)

Humoral and cellular immune responses to CoronaVac up to one year after vaccination
por: Costa, Priscilla Ramos, et al.
Publicado: (2022)

Safety and immunogenicity following a homologous booster dose of CoronaVac in children and adolescents
por: Wang, Lei, et al.
Publicado: (2022)

Heterologous booster vaccination with CoronaVac following prime vaccination with mRNA vaccine
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_bu0cmi94cp9jcqij8dk1nu8st0